Last reviewed · How we verify

HPV vaccine — Competitive Intelligence Brief

HPV vaccine (HPV vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prophylactic vaccine. Area: Oncology / Immunology / Infectious Disease.

marketed Prophylactic vaccine Human papillomavirus (HPV) capsid proteins / L1 antigen Oncology / Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

HPV vaccine (HPV vaccine) — Fondazione IRCCS Policlinico San Matteo di Pavia. HPV vaccine stimulates the immune system to produce antibodies and cellular immunity against human papillomavirus types that cause cervical and other cancers.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
HPV vaccine TARGET HPV vaccine Fondazione IRCCS Policlinico San Matteo di Pavia marketed Prophylactic vaccine Human papillomavirus (HPV) capsid proteins / L1 antigen
Flu Vaccine Flu Vaccine La Fundacion Favaloro para la Investigacion y la Docencia Medica marketed Prophylactic vaccine Influenza A and B viral hemagglutinin and neuraminidase surface antigens
Human Papillomavirus Human Papillomavirus Peking Union Medical College Hospital marketed Prophylactic vaccine Human Papillomavirus capsid protein (L1)
Recombinant Human Papillomavirus Bivalent Vaccine Recombinant Human Papillomavirus Bivalent Vaccine National Cancer Institute (NCI) marketed Prophylactic vaccine Human papillomavirus types 16 and 18 (HPV-16, HPV-18)
Cervarix TM Cervarix TM GlaxoSmithKline phase 3 Prophylactic vaccine HPV types 16 and 18 (L1 capsid protein)
CervarixTM (GSK580299) CervarixTM (GSK580299) GlaxoSmithKline phase 3 Prophylactic vaccine Human papillomavirus (HPV) types 16 and 18
HPV-16/18 vaccine HPV-16/18 vaccine Shanghai Zerun Biotechnology Co.,Ltd phase 3 Prophylactic vaccine HPV-16 and HPV-18 L1 capsid proteins

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prophylactic vaccine class)

  1. GlaxoSmithKline · 5 drugs in this class
  2. La Fundacion Favaloro para la Investigacion y la Docencia Medica · 1 drug in this class
  3. Fondazione IRCCS Policlinico San Matteo di Pavia · 1 drug in this class
  4. National Cancer Institute (NCI) · 1 drug in this class
  5. Peking Union Medical College Hospital · 1 drug in this class
  6. Shanghai Zerun Biotechnology Co.,Ltd · 1 drug in this class
  7. Murdoch Childrens Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HPV vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/hpv-vaccine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: